tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Ami Fadia, 383 are a BUY (88.45%), 46 are a HOLD (10.62%), 4 are a SELL (0.92%).
Analyst Ami Fadia, currently employed at NEEDHAM, carries an average stock price target met ratio of 35.79% that have a potential upside of 25.95% achieved within 157 days. Previously, Ami Fadia worked at LEERINK.
Ami Fadia’s has documented 825 price targets and ratings displayed on 34 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on BIIB, Biogen at 12-Jun-2025.
Analyst best performing recommendations are on RVMD (REVOLUTION MEDICINES).
The best stock recommendation documented was for RVMD (REVOLUTION MEDICINES) at 10/12/2023. The price target of $34 was fulfilled within 4 days with a profit of $9.8 (40.5%) receiving and performance score of 101.24.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Sell
$7
$-6.25 (-47.17%)
$20
1 months 30 days ago
(17-Apr-2025)
8/12 (66.67%)
$-2.11 (-23.16%)
55
Buy
11 months 29 days ago
(18-Jun-2024)
10/37 (27.03%)
$101 (102.02%)
298
Sell
1 years 6 months 27 days ago
(20-Nov-2023)
1/3 (33.33%)
$-0.8 (-0.99%)
300
Hold
$20
$6.75 (50.94%)
$60
1 years 7 months 22 days ago
(25-Oct-2023)
3/22 (13.64%)
$5.72 (40.06%)
40
Hold
$25
$11.75 (88.68%)
$40
1 years 10 months 28 days ago
(19-Jul-2023)
2/5 (40%)
$3.4 (15.74%)
215
Which stock is Ami Fadia is most bullish on?
Which stock is Ami Fadia is most reserved on?
What Year was the first public recommendation made by Ami Fadia?
